you know my target to be happy. 100mil with almost a year getting the word out. Let us see how good the sales staff are
if they are employee not happy with the q1 bonus it can be due to accounting timing. Product is not launched till April 1 (prior to this date test run, for company to keep the 6 month price fix) so the backlog of order(s) going back to last August would not be booked in Q1 for launch in April but booked in Q2 (I can see that making some of the employees upset).
I did see on one of the wholesalers website that they were giving 60 days for payment (just one had the term on their website the others you got to log onto the website to pull omidira)
yahoo analyst estimates has average sales at 2.86m, low of 600k and high of 5.6mil. The low of 600k is crazy just the test docs for Q1 for about a month can exceed the 600k for a 3 month period. The mark is set low.
I doubt a contracted employee would post online. The job they have is a money maker. I would love to sell the only FDA approved drug in the market.
I read the whole thread. I am not sure how credible, though. There was one exchange between 2 people; the first said "we got screwed over the Q1 bonus" and another guy responded by saying "What Q1 bonus? we launched on April 1st!!". I think that shorts are over the place here..No one has any idea about Omidria's uptake other than Omeros.
With a sales force of 40, I am looking for revenue of at least $10 million for this quarter. I could not find any analysts estimates for revenue for this quarter. Good luck to all longs.
thats what i was thinking, looks like a complete waist of a msg board, that is supposedly for sales reps - who knows who these people are.
pretty obvious that the comments are from a short. looks like one clown posting numerous negative comments.
logical negative comments when a stock has 1 out of every four shares "short" Anonymous for a good reason!
it has a thread pertaining to Omeros/omidria, the posters are all anonomous, supposedly sales reps, not necessarily Omeros employees. the entire thread and comments are totally negative about Omidria, sales and lack of sales. i dont know if any is credible, would like an opionon from someone on here about "cafe pharma" msg board ?? tyia
Up 750,000 shares in the latest 2-week reporting period. Now just a hair below ten million shares ...... over 25% of the outstanding shares.
Meanwhile, institutions own over 50%.
Somebody is making a serious mistake and my money says it's the shorts.
Turning her attention to Omeros Corporation, Moussatos is 85% confident of the potential EC approval of Omidria in July. Omidria was approved by the FDA in May 2014 for use during cataract surgery or intraocular lens replacement as a means to maintain pupil size during the surgery. Moussatos recommends the company because it is “advancing a broad pipeline of inflammation and neurological treatment candidates ranging in development stage from FDA approved OMIDRIA™ to Phase 2 to preclinical and the ability to generate in-house new drug candidates from their state-of-the-art drug discovery platforms, which strengthens their intellectual property.” She believes Omeros’s pipeline does not carry so much risk due to its diversity. On May 22, Omeros announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use developed a positive opinion on Opindria. Moussatos notes, “there was no baggage in the CHMP recommendation” and “anticipate[s] full approval of Omidria by the European Commission (EC) is likely to occur in July and provide a catalyst for the stock.”
Liana Moussatos maintained an Outperform rating on Omeros with a $61 price target. She has rated the stock 16 times since March 2012, earning a +40.8% average return per OMER rating.
Overall, Liana Moussatos has a +37.3% average return per rating.
...right at the beginning and then later starting in minute 03:56 into the clip, where the pass-trough status is discussed. Nothing exciting but good to know nevertheless.
agree, but that high was over 3 months ago and lasted barely 1 day. as far as im concerned this is normal for biotec, especially one that isnt generating much revenue YET.
was heavy out of the gate, but yes you are correct. now has slowed to avg. lets hope for good news soon.